|
International Cancer Control Partnership
|
Other
|
CDC
|
NCI
|
The National Cancer Institute and the Union for International Cancer Control convened global partners including the Centers for Disease Control and Prevention (CDC) to cooperate in assisting countries to develop and implement quality cancer plans linked to Non-communicable Disease (NCD) control. This International Cancer Control Partnership, ICCP, believes that prioritizing cancer is critical to reaching the “25x25” goal. ICCP partners will assist countries by: (1) Creating a searchable database of current cancer control plans from around the globe; (2) Performing analysis of gaps and highlighting priority areas for inclusion in plans; (3) Training appropriate personnel to develop plans with targets and evaluation strategies; (4) Providing planners with relevant existing materials and tools; and (5) Offering technical assistance. ICCP partners will use their collective state, country, and regional-level planning experience to guide plan development and implementation and will ensure planners utilize effective, evidence-based strategies to help meet the global NCD targets.
|
|
International Rare Diseases Research Consortium (IRDiRC) Funders'' Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NCATS, NCI, NEI, NHGRI, NIAMS, NINDS
|
The International Rare Diseases Research Consortium (IRDiRC) teams up researchers and organizations investing in rare diseases research in order to achieve two main objectives by the year 2020, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases. A number of grand challenges are being addressed through collaborative actions to reach these 2020 goals such as establishing and providing access to harmonized data and samples, performing the molecular and clinical characterization of rare diseases, boosting translational, preclinical and clinical research, and streamlining ethical and regulatory procedures.
|
|
International TB Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIAID
|
This is a working group of the Federal Tuberculosis (TB) Task Force. The International TB Working Group is chaired and organized by the US Agency for International Development (USAID). It meets monthly to coordinate international TB support.
|
|
Interoperability Standards Advisory Task Force of the Health Information Technology (HIT) Standards Committee
|
Committee, Work group, Advisory group, or Task Force
|
OS
|
NLM
|
The Interoperability Standards Advisory Task Force of the Health Information Technology (HIT) Standards Committee is part of the Federal Advisory Committee that is charged with making recommendations to the Office of the National Coordinator for Health Information Technology (ONC) on standards and implementation specifications to promote interoperability of computer systems and health information.
|
|
Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID, OD/OSP
|
The ISATTAC is a working group of subject matter experts from the Federal Government formed by the Centers for Disease Control and Prevention (CDC) Director to provide recommendations to the CDC''s Division of Select Agents and Toxins in three technical areas: 1) review requests for exclusion of attenuated strains, 2) review requests to conduct restricted experiments, and 3) review select agents and toxins. The Committee conducts a biannual review, required by the Select Agent Rule, of the Select Agents and Toxins list for HHS.
|
|
Investigations of Early Life Determinants of Pediatric and Adult Malignancies in a Population
|
Research Initiative
|
CDC
|
NCI
|
In collaboration with investigators from the US Centers for Disease Control and Prevention (CDC) and the China CDC, the National Cancer Institute (NCI) is assessing the risk of pediatric leukemia and other pediatric cancers in a large population of offspring of mothers enrolled in a community intervention program of peri-conception folic acid supplementation in China. Pediatric cancer risks will be compared in offspring of mothers treated vs offspring of mothers not treated with folic acid supplements.
|
|
It’s a Noisy Planet. Protect Their Hearing® Public Education campaign
|
Public Education Campaign
|
CDC
|
NIDCD
|
The National Institute on Deafness and Other Communication Disorders (NIDCD) sponsors It’s a Noisy Planet Protect Their Hearing®, a national public education campaign to increase awareness among parents of children ages 8 to 12 about noise-induced hearing loss (NIHL) and how to prevent it. The campaign disseminates messages through print and digital materials, social media, community events, school presentations, and other methods. The CDC’s National Center for Environmental Health and National Institute for Occupational Safety and Health (NIOSH) have actively collaborated with the NIDCD for this campaign.
|
|
Joint Agency Nutrition (JAN) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDDK, NICHD, OD/DPCPSI/ODP, OD/DPCPSI/ODS
|
The Joint Agency Nutrition (JAN) was established to address gaps and opportunities in the areas of dietary supplements and nutrition research related to pregnant women and children and chronic diseases. The Working Group reports to the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) Joint Leadership Council.
|
|
Joint External Evaluation Working Group (JEEWG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NCI, NIEHS, NINDS, OD/ORS
|
Supports the Global Health Security Agenda activities related to International Health Regulations implementation to include internal and external joint evaluations, draft a National Action Plan (NAP) to address recommendations, and periodically review and report the status of the NAP.
|
|
Joint Fellowship Program
|
Training Initiative
|
FDA
|
NCI
|
The objective of the National Cancer Institute (NCI) and the Food and Drug Administration (FDA) Joint Fellowship Training Program is to train a cadre of scientists in research and research-related regulatory review, policies, and regulations so that they develop a skill set bridging the two disparate processes. Fellows learn to build awareness of regulatory requirements into the early stages of the medical product development process and develop strategies to improve planning throughout research and regulatory review.
|